Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10497098" target="_blank" >RIV/00179906:_____/25:10497098 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/25:00143758 RIV/61988987:17110/25:A2603DMS RIV/00216208:11110/25:10497098 RIV/00216208:11120/25:43928363 and 7 more
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=WDp1McrF-b" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=WDp1McrF-b</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s12885-025-14087-y" target="_blank" >10.1186/s12885-025-14087-y</a>
Alternative languages
Result language
angličtina
Original language name
Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group
Original language description
Despite significant advancements in therapy of multiple myeloma (MM) over the past 20 years, most patients experience relapse, necessitating new treatment approaches. This study aims to compare the real-world effectiveness of lenalidomide (LEN)-based triplet therapies, specifically daratumumab (DRD), carfilzomib (KRD), and ixazomib (IRD), in relapsed/refractory multiple myeloma (RRMM).A retrospective registry-based study analyzed 538 RRMM patients undergoing therapy for their first to third relapse. The primary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS), with a matching-adjusted indirect comparisons (MAIC) employed to address cohort differences.ORR was highest for DRD at 91.4%, followed by KRD (89.6%) and IRD cohorts (Early-IRD: 79.6%, Late-IRD: 70.8%). Median PFS for DRD was greater at 23.64 months compared to KRD (16.52 months) and IRD groups (Early-IRD: 19.97 months, Late-IRD: 11.57 months). The MAIC confirmed better outcomes for the DRD regimen. High-risk features were not overcome by any of the LEN-based regimens.The findings underscore the superior efficacy of DRD in achieving sustained responses in RRMM patients. The composition of the cohort is a crucial factor, extending beyond selection criteria. This study highlights the importance of real-world evidence in assessing treatment modalities in clinical settings.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
BMC Cancer
ISSN
1471-2407
e-ISSN
1471-2407
Volume of the periodical
25
Issue of the periodical within the volume
APR
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
651
UT code for WoS article
001464287100010
EID of the result in the Scopus database
2-s2.0-105002979787